These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27806321)

  • 1. A network meta-analysis on the efficacy of sixteen targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer.
    Ba-Sang DZ; Long ZW; Teng H; Zhao XP; Qiu J; Li MS
    Oncotarget; 2016 Dec; 7(51):84468-84479. PubMed ID: 27806321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of short-term effectiveness of eight targeted agents combined with chemotherapy for treating esophageal-gastric junction adenocarcinoma: A network meta-analysis.
    He YM; Yu C; Li WB; Li ZP; Xu N
    J Cell Biochem; 2018 Jan; 119(1):1183-1192. PubMed ID: 28708307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective Vascular Endothelial Growth Factor Receptor Inhibitors Provide Limited Benefits for Metastatic Colorectal Cancer: A Meta-Analysis.
    Fan Q; Lv W; Xu Y; Dong Y; Xiang Z; Wang J
    Curr Pharm Des; 2020; 26(26):3171-3186. PubMed ID: 32067605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials.
    Liang RF; Zheng LL
    Drug Des Devel Ther; 2015; 9():4471-8. PubMed ID: 26300630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the addition of targeted biological agents to first-line chemotherapy for advanced colorectal cancer increase complete response? A systematic review and meta-analysis.
    Qi WX; Shen Z; Tang LN; Yao Y
    Colorectal Dis; 2014 Sep; 16(9):O300-7. PubMed ID: 24766530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Regorafenib in Combination with Chemotherapy as Second-Line Treatment in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis and Systematic Literature Review.
    Xie X; Zhang J; Hu H; Cai Y; Wu Z; Ling J; Li W; Deng Y
    Adv Ther; 2020 Oct; 37(10):4233-4248. PubMed ID: 32770529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor sidedness and efficacy of first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer: A network meta-analysis.
    Wu CC; Wang JH; Lin PC; Liang CA; Huang CY; Lien HC; Chen CY; Chou KJ; Su YC
    Crit Rev Oncol Hematol; 2020 Jan; 145():102823. PubMed ID: 31783291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.
    Siu LL; Shapiro JD; Jonker DJ; Karapetis CS; Zalcberg JR; Simes J; Couture F; Moore MJ; Price TJ; Siddiqui J; Nott LM; Charpentier D; Liauw W; Sawyer MB; Jefford M; Magoski NM; Haydon A; Walters I; Ringash J; Tu D; O'Callaghan CJ
    J Clin Oncol; 2013 Jul; 31(19):2477-84. PubMed ID: 23690424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis.
    Li Z; Huang Y; Zhao R; Cui Y; Zhou Y; Wu X
    Sci Rep; 2018 Jan; 8(1):510. PubMed ID: 29323221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
    Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
    Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
    Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
    Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Zheng B; Wang X; Wei M; Wang Q; Li J; Bi L; Deng X; Wang Z
    BMC Cancer; 2019 Mar; 19(1):280. PubMed ID: 30922269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts.
    Tsukihara H; Nakagawa F; Sakamoto K; Ishida K; Tanaka N; Okabe H; Uchida J; Matsuo K; Takechi T
    Oncol Rep; 2015 May; 33(5):2135-42. PubMed ID: 25812794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial.
    Fuchs CS; Fakih M; Schwartzberg L; Cohn AL; Yee L; Dreisbach L; Kozloff MF; Hei YJ; Galimi F; Pan Y; Haddad V; Hsu CP; Sabin A; Saltz L
    Cancer; 2013 Dec; 119(24):4290-8. PubMed ID: 24122767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.
    Saltz L; Badarinath S; Dakhil S; Bienvenu B; Harker WG; Birchfield G; Tokaz LK; Barrera D; Conkling PR; O'Rourke MA; Richards DA; Reidy D; Solit D; Vakiani E; Capanu M; Scales A; Zhan F; Boehm KA; Asmar L; Cohn A
    Clin Colorectal Cancer; 2012 Jun; 11(2):101-11. PubMed ID: 22055112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination adjuvant chemotherapy with targeted drugs for treatment of colorectal cancer: A network meta-analysis.
    Wang J; Luo L; Wang D; Guo B; Li J; Yang Z; Tang D
    J Cell Biochem; 2018 Feb; 119(2):1521-1537. PubMed ID: 28771807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
    Köhne CH; Lenz HJ
    Oncologist; 2009 May; 14(5):478-88. PubMed ID: 19411318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer.
    Giusti RM; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2009 Mar; 14(3):284-90. PubMed ID: 19282350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.